Display options
Share it on

PLoS One. 2011;6(6):e20343. doi: 10.1371/journal.pone.0020343. Epub 2011 Jun 03.

Prevalence of drug-resistant tuberculosis in mainland China: systematic review and meta-analysis.

PloS one

Yu Yang, Xiangwei Li, Feng Zhou, Qi Jin, Lei Gao

Affiliations

  1. State Key Laboratory for Molecular Virology and Genetic Engineering, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

PMID: 21674033 PMCID: PMC3108589 DOI: 10.1371/journal.pone.0020343

Abstract

BACKGROUND: The spread of drug-resistant tuberculosis (TB) is one of the major public health problems in the world. Surveillance of anti-TB drug resistance is important for monitoring TB control strategies. However, the status of drug-resistant TB in China has been reported inconsistently.

METHODS: We systematically reviewed published studies on drug-resistant TB in China until March 31, 2011, and quantitatively summarized prevalence and patterns of anti-TB drug resistance among new cases and previously treated cases, respectively.

RESULTS: Ninety-five eligible articles, published during 1993-2011, were included in this review. The meta-analyses showed that the prevalence of drug-resistant TB in new cases was 27.9% (95% CI, 25.6%-30.2%) (n/N = 27,360/104,356) and in previously treated cases was 60.3% (95% CI, 56.2%-64.2%) (n/N = 30,350/45,858). Furthermore, in these two study populations, the prevalence of multiple drug resistance was found to be 5.3% (95% CI, 4.4%-6.4%) (n/N = 8810/101,718) and 27.4% (95% CI, 24.1%-30.9%) (n/N = 10,486/44,530) respectively. However, the results were found to be frequently heterogeneous (p for Q tests <0.001). The most common resistance was observed for isoniazid among both study populations. Different patterns of drug resistance were observed in the subgroup analysis with respect to geographic areas, drug susceptibility testing methods and subject enrollment time.

CONCLUSIONS: Results of meta-analyses indicated a severe status of drug-resistant TB in China, which attaches an importance to strength TB prevention and control.

References

  1. Int J Tuberc Lung Dis. 2010 Jan;14(1):15-23 - PubMed
  2. Zhonghua Jie He He Hu Xi Za Zhi. 2002 Jan;25(1):3-7 - PubMed
  3. Health Policy Plan. 2006 Sep;21(5):365-72 - PubMed
  4. Int J Tuberc Lung Dis. 2009 Feb;13(2):253-9 - PubMed
  5. Dtsch Arztebl Int. 2010 Jan;107(1-2):10-9 - PubMed
  6. Jpn J Infect Dis. 2010 Sep;63(5):368-71 - PubMed
  7. Int J Tuberc Lung Dis. 2010 Feb;14(2):131-40 - PubMed
  8. Bull World Health Organ. 2002;80(6):430-6 - PubMed
  9. PLoS Med. 2009 Sep;6(9):e1000150 - PubMed
  10. BMJ. 2003 Sep 6;327(7414):557-60 - PubMed
  11. Mem Inst Oswaldo Cruz. 2010 Sep;105(6):838-41 - PubMed
  12. Int J Tuberc Lung Dis. 2010 Jun;14(6):672-82 - PubMed
  13. Lancet. 2009 May 30;373(9678):1861-73 - PubMed
  14. Clin Infect Dis. 2010 May 15;50 Suppl 3:S156-64 - PubMed
  15. Health Policy Plan. 2008 Jan;23(1):43-55 - PubMed
  16. Int J Tuberc Lung Dis. 2010 Apr;14(4):382-90 - PubMed
  17. Clin Orthop Relat Res. 2005 Aug;(437):3-6 - PubMed
  18. J Infect Dis. 2006 Aug 15;194(4):479-85 - PubMed

MeSH terms

Publication Types